Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis

Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis

(2014) M. A. Nowell et al.   JOURNAL OF IMMUNOLOGY

The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis

(2011) Wenhong Wang et al.   RHEUMATOLOGY INTERNATIONAL

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

TGF-β indirectly favors the development of human Th17 cells by inhibiting Th1 cells

(2009) Veronica Santarlasci et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Plasticity of T-cell phenotype and function: the T helper type 17 example

(2009) Ariana Peck et al.   IMMUNOLOGY

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Human interleukin 17–producing cells originate from a CD161+CD4+T cell precursor

(2008) Lorenzo Cosmi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET